Proqr Therapeutics (PRQR) Stock Price, Quote & News

Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Re...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 88 166 7000

Website: www.proqr.com

Address:

Zernikedreef 9, Leiden, Netherlands

SaluteYourShorts Oct. 24 at 5:39 PM

$PRQR 50~!

1 · Reply

FutureInvesting777 Oct. 24 at 5:23 PM

$PRQR no comments :) !

0 · Reply

Universaal Oct. 24 at 4:54 PM

$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both

0 · Reply

Universaal Oct. 24 at 10:47 AM

$PRQR investor comes bottom to this mgmt. they do nothing to protect the SP.

0 · Reply

ehpats Oct. 23 at 12:06 PM

$PRQR is this the set up for a stop loss raid 🤷

2 · Reply

dirkfrank Oct. 23 at 11:36 AM

$PRQR premarket 😳

2 · Reply

Universaal Oct. 23 at 3:31 AM

$PRQR it’s pure trash 🗑️

0 · Reply

dirkfrank Oct. 22 at 8:52 PM

$PRQR nice gains gone in two horrible days

0 · Reply

ehpats Oct. 22 at 3:43 PM

$PRQR expect some games to be played over the next couple weeks waiting on upcoming call Nov 3rd. Those wanting shares will do some stop loss hunting and other manipulation to acquire shares.

1 · Reply

FutureInvesting777 Oct. 22 at 3:34 PM

$PRQR no comments :)

1 · Reply

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Oct 13, 2025, 8:30 AM EDT - 12 days ago

ProQR to Participate in Upcoming Investor Conferences in October 2025

Aug 7, 2025, 7:00 AM EDT - 2 months ago

ProQR Announces Second Quarter 2025 Operating and Financial Results

Jul 28, 2025, 8:00 AM EDT - 3 months ago

ProQR Announces Upcoming Presentation at RNA Editing Summit

Jun 26, 2025, 4:30 PM EDT - 4 months ago

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

May 12, 2025, 8:00 AM EDT - 5 months ago

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 8, 2025, 7:00 AM EDT - 6 months ago

ProQR Announces First Quarter 2025 Operating and Financial Results

May 2, 2025, 8:00 AM EDT - 6 months ago

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

May 1, 2025, 8:00 AM EDT - 6 months ago

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Apr 14, 2025, 7:00 AM EDT - 6 months ago

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Mar 13, 2025, 7:00 AM EDT - 8 months ago

ProQR Announces Year End 2024 Operating and Financial Results

Dec 10, 2024, 8:00 AM EST - 11 months ago

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

Oct 25, 2024, 4:45 PM EDT - 1 year ago

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 10:15 PM EDT - 1 year ago

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

Oct 22, 2024, 4:01 PM EDT - 1 year ago

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 10, 2024, 4:30 PM EDT - 1 year ago

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

May 11, 2024, 5:57 PM EDT - 1 year ago

ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)

May 9, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces First Quarter 2024 Operating and Financial Results

Apr 23, 2024, 7:00 AM EDT - 1 year ago

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Apr 22, 2024, 4:31 PM EDT - 1 year ago

ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting

Apr 19, 2024, 7:00 AM EDT - 1 year ago

ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Mar 13, 2024, 7:00 AM EDT - 1 year ago

ProQR Announces Year End 2023 Operating and Financial Results

Jan 19, 2024, 7:00 AM EST - 1 year ago

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Jan 5, 2024, 7:00 AM EST - 1 year ago

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Dec 8, 2023, 7:30 AM EST - 2 years ago

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Nov 7, 2023, 7:00 AM EST - 2 years ago

ProQR Announces Third Quarter 2023 Operating and Financial Results

Nov 6, 2023, 7:00 AM EST - 2 years ago

ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Sep 28, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Sep 7, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 2 years ago

ProQR Announces Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:00 AM EDT - 2 years ago

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR's Sepofarsen and Ultevursen Ophthalmic Assets

Jul 9, 2023, 6:53 AM EDT - 2 years ago

ProQR: Too Many Failures For Its RNA Technology

Jul 6, 2023, 7:00 AM EDT - 2 years ago

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

May 9, 2023, 8:00 AM EDT - 2 years ago

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Apr 20, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Upcoming Investor Conferences in April and May

Apr 18, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Mar 29, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Mar 14, 2023, 8:00 AM EDT - 2 years ago

ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Mar 7, 2023, 8:00 AM EST - 2 years ago

ProQR to Present at Upcoming Scientific and Industry Conferences

Dec 22, 2022, 9:12 AM EST - 3 years ago

ProQR's stock jumps on expanded RNA deal with Lilly

LLY

Dec 22, 2022, 6:15 AM EST - 3 years ago

ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Dec 22, 2022, 6:00 AM EST - 3 years ago

Lilly and ProQR to Expand RNA Editing Collaboration

LLY

Nov 14, 2022, 4:30 PM EST - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022

Nov 9, 2022, 7:00 AM EST - 3 years ago

ProQR Announces Third Quarter 2022 Operating and Financial Results

Aug 11, 2022, 7:00 AM EDT - 3 years ago

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Jun 1, 2022, 7:00 AM EDT - 3 years ago

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

May 9, 2022, 7:00 AM EDT - 3 years ago

ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022

May 5, 2022, 4:30 PM EDT - 3 years ago

ProQR Announces First Quarter 2022 Operating and Financial Results

Apr 26, 2022, 4:10 PM EDT - 3 years ago

ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022

SaluteYourShorts Oct. 24 at 5:39 PM

$PRQR 50~!

1 · Reply

FutureInvesting777 Oct. 24 at 5:23 PM

$PRQR no comments :) !

0 · Reply

Universaal Oct. 24 at 4:54 PM

$PRQR few companies i never trust mgmt $PRQR $VSTM bcz these two never gives a fk about their investors I own both

0 · Reply

Universaal Oct. 24 at 10:47 AM

$PRQR investor comes bottom to this mgmt. they do nothing to protect the SP.

0 · Reply

ehpats Oct. 23 at 12:06 PM

$PRQR is this the set up for a stop loss raid 🤷

2 · Reply

dirkfrank Oct. 23 at 11:36 AM

$PRQR premarket 😳

2 · Reply

Universaal Oct. 23 at 3:31 AM

$PRQR it’s pure trash 🗑️

0 · Reply

dirkfrank Oct. 22 at 8:52 PM

$PRQR nice gains gone in two horrible days

0 · Reply

ehpats Oct. 22 at 3:43 PM

$PRQR expect some games to be played over the next couple weeks waiting on upcoming call Nov 3rd. Those wanting shares will do some stop loss hunting and other manipulation to acquire shares.

1 · Reply

FutureInvesting777 Oct. 22 at 3:34 PM

$PRQR no comments :)

1 · Reply

johnnygogogo Oct. 22 at 3:32 PM

$PRQR this will go up after Hodor and crew have their stop losses hit.

0 · Reply

justfacts1 Oct. 22 at 1:33 AM

$PRQR waiting for new high!

0 · Reply

ehpats Oct. 21 at 7:07 PM

$PRQR P1 trail design will give more substantial data than the typical P1 which is primarily safety and tolerability.

0 · Reply

ehpats Oct. 21 at 5:54 PM

$PRQR so listening to the call today it sounds like the Nov 3rd conference is when we can expect updated timelines and for P1 data readouts.

1 · Reply

Universaal Oct. 21 at 3:50 PM

$PRQR not selling till $10 plus

0 · Reply

SaluteYourShorts Oct. 21 at 3:04 PM

$PRQR up near 20% on pos.. waiting for a few hund %

1 · Reply

Universaal Oct. 21 at 11:30 AM

$PRQR still waiting for AX -1412. Per schedule it supposed to be released mid 2025. no idea these europha stocks never updates

0 · Reply

ehpats Oct. 20 at 8:16 PM

$PRQR nice to see a close over $3 on a Monday. Hopefully the buying pressure continues all week.

1 · Reply

justfacts1 Oct. 20 at 5:12 PM

$PRQR we should be above 3 with this news.

1 · Reply

thom4stu Oct. 20 at 1:08 PM

$PRQR CTA Authorized… https://www.proqr.com/press-releases/proqr-receives-cta-authorization-for-ax-0810-and-announces-virtual-investor-and-analyst-event-on-november-3-2025

0 · Reply

Universaal Oct. 20 at 12:15 PM

$PRQR I’m not following this as much, not sure any of these 2025 events has happened according to this schedule?? I doubt it.

0 · Reply

Stockswingalert Oct. 20 at 12:06 PM

$PRQR $RNA $RNAC $WVE $XBI https://www.stocktitan.net/news/PRQR/pro-qr-receives-cta-authorization-for-ax-0810-and-announces-virtual-4b4910ofj7dt.html

1 · Reply

Market Cap	296.70M
Revenue (ttm)	20.46M
Net Income (ttm)	-30.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-146.82%
Debt to Equity Ratio	0.07

Volume	394,200
Avg Vol	484,578
Day's Range	N/A - N/A
Shares Out	105.21M
Stochastic %K	79%
Beta	0.23
Analysts	Strong Sell
Price Target	$8.88